PKTX
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | 0.00 | $0 | $26,756 |
| 2025 Q2 | -0.00 | $0 | -$84,865 |
| 2025 Q1 | -0.00 | $0 | -$51,970 |
| 2024 Q4 | -0.00 | $48,680 | -$50,387 |
| 2024 Q3 | -0.00 | $0 | -$3,600 |
| 2024 Q2 | -0.00 | $0 | -$106,636 |
| 2024 Q1 | -0.00 | $0 | -$67,572 |
| 2023 Q4 | -0.00 | $0 | -$101,988 |